PE20130314A1 - PORCIONES DE ENLACE A ANTI-C5a CON ALTA ACTIVIDAD DE BLOQUEO - Google Patents

PORCIONES DE ENLACE A ANTI-C5a CON ALTA ACTIVIDAD DE BLOQUEO

Info

Publication number
PE20130314A1
PE20130314A1 PE2012000715A PE2012000715A PE20130314A1 PE 20130314 A1 PE20130314 A1 PE 20130314A1 PE 2012000715 A PE2012000715 A PE 2012000715A PE 2012000715 A PE2012000715 A PE 2012000715A PE 20130314 A1 PE20130314 A1 PE 20130314A1
Authority
PE
Peru
Prior art keywords
link
seq
portions
blocking activity
high blocking
Prior art date
Application number
PE2012000715A
Other languages
English (en)
Inventor
Renfeng Guo
Niels Christoph Riedemann
Yan Li
Beifen Shen
Original Assignee
Inflarx Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41683202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130314(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inflarx Gmbh filed Critical Inflarx Gmbh
Publication of PE20130314A1 publication Critical patent/PE20130314A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/14Peptides, e.g. proteins
    • A61K49/16Antibodies; Immunoglobulins; Fragments thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)

Abstract

SE REFIERE A UNA PORCION DE ENLACE QUE SE ENLAZA A UN EPITOPO CONFORMACIONAL DE C5a SELECCIONADO DE LA SIGUIENTES SECUENCIAS DE AMINOACIDOS: SEQ ID Nº 18, SEQ ID Nº 19, SEQ ID Nº 4, SEQ ID Nº 38, SEQ ID Nº 39, ENTRE OTROS, DONDE DICHA PORCION DE ENLACE SE SELECCIONA DEL GRUPO QUE CONSISTE DE ANTICUERPOS O FRAGMENTOS DE ENLACE A ANTIGENOS, OLIGONUCLEOTIDOS, PROTEINAS SIMILARES A ANTICUERPO PEPTIDOMETICOS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHA PORCION DE ENLACE ES UTIL COMO AGENTE ACTIVO EN UNA COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO Y/O PREVENCION DE ENFERMEDADES INFLAMATORIAS AGUDAS
PE2012000715A 2009-11-26 2010-11-26 PORCIONES DE ENLACE A ANTI-C5a CON ALTA ACTIVIDAD DE BLOQUEO PE20130314A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26469609P 2009-11-26 2009-11-26
EP09014745A EP2327725A1 (en) 2009-11-26 2009-11-26 Anti-C5a binding moieties with high blocking activity

Publications (1)

Publication Number Publication Date
PE20130314A1 true PE20130314A1 (es) 2013-04-03

Family

ID=41683202

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000715A PE20130314A1 (es) 2009-11-26 2010-11-26 PORCIONES DE ENLACE A ANTI-C5a CON ALTA ACTIVIDAD DE BLOQUEO

Country Status (26)

Country Link
US (4) US8802096B2 (es)
EP (4) EP2327725A1 (es)
JP (4) JP6104605B2 (es)
KR (3) KR20180034690A (es)
CN (2) CN105037541A (es)
AU (1) AU2010324141B2 (es)
BR (1) BR112012012514B1 (es)
CA (1) CA2780520C (es)
CL (1) CL2012001304A1 (es)
CY (2) CY1118463T1 (es)
DK (2) DK3181582T3 (es)
EA (1) EA022759B1 (es)
ES (2) ES2613352T3 (es)
HR (2) HRP20170041T1 (es)
HU (2) HUE032543T2 (es)
IL (1) IL219911A (es)
LT (2) LT3181582T (es)
MX (1) MX2012006060A (es)
NZ (1) NZ600348A (es)
PE (1) PE20130314A1 (es)
PL (2) PL2504362T3 (es)
PT (2) PT2504362T (es)
RS (2) RS55571B1 (es)
SI (2) SI2504362T1 (es)
SM (1) SMT201700054B (es)
WO (1) WO2011063980A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
LT2708559T (lt) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
US8703129B2 (en) 2008-09-07 2014-04-22 GlycoNex, Inc. Antibodies against extended type 1 chain antigens, derivatives thereof and use
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
AU2011245117B2 (en) 2010-04-30 2015-03-12 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
AU2012272706B2 (en) 2011-06-22 2017-07-06 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
PL2817329T3 (pl) * 2012-02-20 2019-07-31 Swedish Orphan Biovitrum Ab (Publ) Polipeptydy wiążące z c5 ludzkiego dopełniacza
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
MY176200A (en) 2013-08-28 2020-07-24 Affibody Ab Binding polypeptides having a mutated scaffold
KR102446636B1 (ko) 2013-08-28 2022-09-23 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) 인간 보체 c5에 결합하는 안정한 폴리펩티드
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
MX2016011862A (es) * 2014-03-20 2016-12-05 Inflarx Gmbh Inhibidores de c5a para el tratamiento de la neumonia viral.
WO2016040294A2 (en) 2014-09-09 2016-03-17 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
NZ732753A (en) 2014-12-04 2024-08-30 Janssen Biotech Inc Anti-cd38 antibodies for treatment of acute myeloid leukemia
MY183415A (en) 2014-12-19 2021-02-18 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
KR102602754B1 (ko) 2015-05-20 2023-11-14 얀센 바이오테크 인코포레이티드 경쇄 아밀로이드증 및 다른 cd38-양성 혈액학적 악성종양을 치료하기 위한 항-cd38 항체
ES2890783T3 (es) 2015-06-22 2022-01-24 Janssen Biotech Inc Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-CD38 e inhibidores de survivina
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CN108472369A (zh) 2015-11-03 2018-08-31 詹森生物科技公司 抗cd38抗体的皮下制剂及其用途
CN106957366B (zh) * 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用
WO2017196960A1 (en) * 2016-05-10 2017-11-16 Annexon, Inc. Anti-complement factor c4/c4b antibodies and uses thereof
UA124734C2 (uk) 2016-06-14 2021-11-10 Рідженерон Фармасьютікалз, Інк. Антитіло проти с5 і його застосування
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
CA3055541A1 (en) * 2017-03-06 2018-09-13 The Trustees Of The University Of Pennsylvania Anti-c5 antibodies and uses thereof
EP3600421A4 (en) * 2017-03-23 2021-01-06 The Trustees of The University of Pennsylvania ANTI-C5A ANTIBODIES AND USES THEREOF
EP4272821A3 (en) 2017-04-03 2024-01-03 InflaRx GmbH Treatment of inflammatory diseases with inhibitors of c5a activity
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
KR20200020727A (ko) 2017-06-23 2020-02-26 인플라알엑스 게엠베하 C5a 활성의 억제제를 사용한 염증 질병의 치료
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
EP3724226A1 (en) 2017-12-13 2020-10-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
EP3586865A1 (en) 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
CN109053882B (zh) * 2018-08-28 2019-08-23 东莞市朋志生物科技有限公司 一种ns1蛋白的结合蛋白以及应用
EP3846850A4 (en) 2018-09-06 2022-06-15 The Trustees of the University of Pennsylvania HUMANIZED ANTI-C5 ANTIBODIES AND THEIR USES
US20230158060A1 (en) 2020-03-27 2023-05-25 Inflarx Gmbh Inhibitors of C5a for the Treatment of Corona Virus Infection
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗c5a抗體
CN118791602A (zh) * 2020-06-24 2024-10-18 舒泰神(北京)生物制药股份有限公司 特异性识别c5a的抗体及其应用
MX2023008302A (es) 2021-01-13 2023-09-25 Visterra Inc Anticuerpos humanizados contra el receptor 1 del componente 5a del complemento y métodos de uso de estos.
WO2023050233A1 (en) * 2021-09-29 2023-04-06 The Trustees Of The University Of Pennsylvania Humanized anti-c5a antibodies and uses thereof
CN116670288A (zh) * 2021-12-22 2023-08-29 舒泰神(北京)生物制药股份有限公司 一种分离的抗C5a抗体及其制剂与应用
WO2023186054A1 (zh) * 2022-04-02 2023-10-05 舒泰神(北京)生物制药股份有限公司 特异性识别c5a的抗体及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
AU6501390A (en) 1989-09-21 1991-04-18 Synergen, Inc. Method for transporting compositions across the blood brain barrier
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6673346B1 (en) * 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP3372243A1 (en) * 2001-08-17 2018-09-12 Genentech, Inc. Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b
US7432356B2 (en) 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
JP2005535572A (ja) * 2002-04-12 2005-11-24 メディミューン,インコーポレーテッド 組換え抗インターロイキン−9抗体
EP2327725A1 (en) * 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
AU2011245117B2 (en) 2010-04-30 2015-03-12 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies

Also Published As

Publication number Publication date
US20170002067A1 (en) 2017-01-05
JP2016074721A (ja) 2016-05-12
CA2780520C (en) 2021-11-23
HRP20170041T1 (hr) 2017-03-10
PT3181582T (pt) 2020-03-03
EA022759B1 (ru) 2016-02-29
HUE049376T2 (hu) 2020-09-28
DK3181582T3 (da) 2020-02-24
EP2327725A1 (en) 2011-06-01
ES2773725T3 (es) 2020-07-14
KR20120089346A (ko) 2012-08-09
CY1122674T1 (el) 2021-03-12
RS59955B1 (sr) 2020-03-31
HUE032543T2 (en) 2017-10-30
SI2504362T1 (sl) 2017-03-31
US9073983B2 (en) 2015-07-07
JP2019163266A (ja) 2019-09-26
KR102112969B1 (ko) 2020-05-19
HRP20200241T1 (hr) 2020-06-12
KR101844611B1 (ko) 2018-04-02
AU2010324141A1 (en) 2012-06-21
CL2012001304A1 (es) 2012-08-03
BR112012012514A2 (pt) 2020-07-28
BR112012012514B1 (pt) 2022-10-04
US10774136B2 (en) 2020-09-15
US8802096B2 (en) 2014-08-12
US20140314772A1 (en) 2014-10-23
US9458233B2 (en) 2016-10-04
EP2504362A1 (en) 2012-10-03
JP2013512209A (ja) 2013-04-11
JP2018080170A (ja) 2018-05-24
LT2504362T (lt) 2017-02-10
MX2012006060A (es) 2012-06-19
LT3181582T (lt) 2020-02-25
US20150266949A1 (en) 2015-09-24
JP6591272B2 (ja) 2019-10-16
EP3181582A1 (en) 2017-06-21
PL2504362T3 (pl) 2017-08-31
ES2613352T3 (es) 2017-05-24
CY1118463T1 (el) 2017-07-12
JP6104605B2 (ja) 2017-03-29
US20120231008A1 (en) 2012-09-13
KR20180034690A (ko) 2018-04-04
IL219911A (en) 2017-03-30
WO2011063980A1 (en) 2011-06-03
RS55571B1 (sr) 2017-05-31
SMT201700054B (it) 2017-03-08
SI3181582T1 (sl) 2020-03-31
CN102741283B (zh) 2015-07-15
EP2504362B1 (en) 2016-11-23
AU2010324141B2 (en) 2014-04-10
CN102741283A (zh) 2012-10-17
KR20190039357A (ko) 2019-04-10
DK2504362T3 (en) 2017-01-30
EP3670532A1 (en) 2020-06-24
PL3181582T3 (pl) 2020-06-01
NZ600348A (en) 2014-01-31
EP3181582B1 (en) 2020-01-29
EA201200795A1 (ru) 2013-04-30
CA2780520A1 (en) 2011-06-03
CN105037541A (zh) 2015-11-11
PT2504362T (pt) 2017-01-18
IL219911A0 (en) 2012-07-31

Similar Documents

Publication Publication Date Title
PE20130314A1 (es) PORCIONES DE ENLACE A ANTI-C5a CON ALTA ACTIVIDAD DE BLOQUEO
CL2018000537A1 (es) Anticuerpo anti-factor d del complemento; polinucleótido codificante; vector que comprende dicho polinucleótido; célula húesped que comprende dicho vector; método de fabricación de anticuerpo; composición farmacéutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares (divisional de cl 1001-2009).
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
AR083740A1 (es) Anticuerpos dkk1 (dickkopf-1) y metodos de uso
PE20230404A1 (es) Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
ITMI20021527A1 (it) Anticorpi anti componente c5 del complemento e loro uso
MX2015005328A (es) Composiciones y metodos para la administracion selectiva de moleculas de oligonucleotidos a tipos de celulas.
BR112012018951C8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BR112012018947B8 (pt) anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica
BR112014021102A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
BR112017018383A2 (pt) inclusão de éxon2 induzida por anti-sentido em alfa-glucosidase ácida
BR112013026032A2 (pt) composições nutricionais incluindo ácidos graxos de cadeia ramificada para cicatrização de ferida
AR093803A1 (es) Composiciones y metodos de anticuerpos de marcaje de epo
BRPI1007379B8 (pt) composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli
BR112012012918A8 (pt) Agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
BR112014021101A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna e método de tratamento e/ou prevenção de câncer, uso de um anticorpo
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
MX342764B (es) Composiciones y metodos para la distribucion selectiva de moleculas de oligonucleotidos a tipos especificos de neuronas.
MA40057A (fr) Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants
TR201818825T4 (tr) Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar
AR099303A1 (es) Construcciones de aptámeros
BR112013007069A2 (pt) métodos para tratar doença autoimune usando nanoesferas biocompatíveis e bioabsorvíveis
RU2013126581A (ru) Мутанты стрептокиназы и их ковалентно модифицированные формы
WO2011038933A3 (en) Anti-hsv antibody

Legal Events

Date Code Title Description
FG Grant, registration